Syncom Formulations Approves Quarterly Results, Announces Dividend Recommendation, and Key Management Changes

<h1>Syncom Formulations Approves Quarterly Results, Announces Dividend Recommendation, and Key Management Changes</h1>

Syncom Formulations (India) Limited announced several significant outcomes from its Board of Directors meeting held on August 11, 2026. The board reviewed the company's performance for the quarter ending June 30, 2026, approved the company's forthcoming annual general meeting details, and confirmed key executive changes within the organization.

The management decisions included the approval of the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. Furthermore, the board took on record the Limited Review Report provided by the Auditors concerning the company's financial results for the same period.

In preparation for the upcoming general meeting, the directors approved the Board's Report and the notice for the 38th Annual General Meeting (AGM). This AGM is scheduled to be held on Wednesday, September 30, 2026, via Video Conferencing or other Audio-Visual Means. The board also finalized the annual book closure procedures and determined the cut-off date for eligibility in the Remote E-voting process at the 38th AGM, approving the appointment of a Scrutinizer for this purpose.

Key Appointments and Director Changes​

The company addressed several important changes regarding its leadership team during the board meeting. The directors noted the resignation of Shri Kedarmal Shankarlal Bankda from the position of Whole-time Director, effective August 11, 2026. Additionally, the board noted the resignations of Shri Vijay Shankarlal Bankda as Managing Director and Shri Rahul Vijay Bankda as Chief Financial Officer (CFO), both effective August 11, 2026.

The board subsequently approved several appointments and designatory changes, effective from August 12, 2026:

• Mrs. Rinki Ankit Bankda was approved for appointment as an Additional Director and designated as Whole Time Director, pending member approval within three months of her appointment.
• Shri Rahul Vijay Bankda was approved for the appointment as an Additional Director and designated as Managing Director of the Company, also subject to members' approval within a period of three months.
• Shri Ankur Vijay Bankda was approved for the appointment as CFO.

The board also recommended the re-appointment of Smt. Ruchi Jindal as Woman Independent Director effective June 29, 2027, pending shareholder approval at the AGM. The appointment of a Cost Auditor and the Internal Auditor were also decided by the board; the remuneration for the Cost Auditor remains subject to ratification by shareholders at the ensuing AGM.

Dividend Recommendation and Record Date​

The Board recommended a final dividend of Re. 0.10/- (10%) per equity share, with each equity share valued at Rs. 1/-, pending approval from the shareholders at the Annual General Meeting.

To determine the list of shareholders entitled to receive this dividend for the financial year ended March 31, 2026, the Record Date has been set as Wednesday, September 23, 2026. The details related to the record date and final dividend are provided in Annexure 1.

SYNCOMF Stock Price Movement​

Today, shares of Syncom Formulations (India) Limited rallied in the market, closing higher by 1.81% to settle at ₹14.53. The equity saw significant activity, with over 4.93 million shares traded during the session.